|
name click to compare prices |
» Shop local, ethical and at the best price on Ethishop |
|
|
|
Business & market
Subsidiaries
Locations & production
shareholder | country | % | source |
|
year name | photo position; compensation source |
|
year | employees <> | social impact : country source |
2005 | -350 | Closure/Bankruptcy: Closes down production of bulk vitamin C in the US and cuts costs at its plant in Dalry, Scotland: | Nutra-ingredients USA |
2004 | -420 | | Le Bulletin des agriculteurs |
2004 | -400 | Relocation: Will restructure its money-losing anti-infectives business, closing capacity in Europe and increasing output in Asia. 13% of the business's total will go. Weak markets, the decline of the dollar, and strong growth in Asia are cited as main reasons for the restructuring. A plant at Delft and a plant at Geleen, the Netherlands, will close in 2005. A joint venture with Glaxo SmithKline at Irvine, UK is to end in 2005. DSM is to expand and upgrade production at its anti-infectives plant at Toansa, India, and at its joint venture's at Harbin, Zhang Jiakou, and Zibo, China. The restructuring should mean annualized cost savings of tens of millions of euros within two years.: | European Restructuring Monitor |
2004 | -39 | Internal restructuring: | Edicom |
|
year | employees <> | social impact : country source |
|
year |   | sales | income | | | source |
2004 |
| 7,75 | 0,26 | |   | billion Eu€ | |
2003 |
| 6,05 | 0,14 | |   | billion Eu€ | |
2002 |
| 6,66 | 1,19 | |   | billion Eu€ | |
2001 |
| 7,97 | 1,42 | |   | billion Eu€ | |
2000 |
| 8,09 | 0,58 | |   | billion Eu€ | |
1999 |
| 6,33 | 0,37 | |   | billion Eu€ | |
|
year | financial misdemeanor | sales | income | assets | buyback | source |
|
year | purpose : intermediary/lobby : institution source |
|
|
|